# Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-Brazil

> **NCT01365091** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 112 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Saxagliptin/metformin fixed-dose combination (FDC)
- **DRUG:** Saxagliptin
- **DRUG:** Metformin extended-release (XR)
- **DRUG:** Saxagliptin/Metformin FDC
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT01365091
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2015-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01365091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01365091, "Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-Brazil". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01365091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*